Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Japan’s 1st Herceptin Biosimilar Now Available, but Use Limited to Gastric Cancer
Nippon Kayaku said on August 20 that it launched a biosimilar version of the major cancer drug Herceptin (trastuzumab) in Japan the same day after it won approval in March for the treatment of HER-2 overexpressing, unresectable, advanced/relapsed gastric cancer.…
To read the full story
Related Article
- Celltrion/Nippon Kayaku Herceptin Biosimilars Get OK for New Breast Cancer Dosing Schedule
August 22, 2019
- Celltrion Launches Herceptin Biosimilar in Japan
August 29, 2018
- Chugai Drops Patent Suit over Nippon Kayaku’s Herceptin Biosimilar
April 12, 2018
- Japan Approves 1st Herceptin Biosimilar for Gastric Cancer
March 26, 2018
- Japan’s 1st Herceptin Biosimilar Clears MHLW Panel, Now in Line for March Approval for Gastric Cancer
February 5, 2018
- Chugai Sues Nippon Kayaku over Herceptin Patent
September 11, 2017
- 1st Herceptin Biosimilar Filed in Japan: Nippon Kayaku
April 12, 2017
BUSINESS
- GNI Targets Above-Industry Growth in Japan after Ayumi Buyout
July 3, 2026
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
- Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
- Otsuka’s Voyxact Shows Two-Year Kidney Benefit in PIII IgAN Trial
July 3, 2026
- PeptiDream, NCC Start FIH Study of CLDN18.2 Radiopharmaceutical
July 3, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…